Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytarabine Therapeutic Follow-up in AML
NCT03337516Unknown
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Jun 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cytarabine in acute myeloid leukemia (AML), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoints: Measurements of circulating levels of cytarabine and its metabolites and Assessment of genetic polymorphism of somatic Cytidine Deaminase (CDA) and Déoxycitidine Kinase (dCK). Status: unknown.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03337516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03337516.